3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
36
Carboplatin
28
Paclitaxel
23
Filgrastim
17
Nivolumab
14
Gemcitabine
14
Cyclophosphamide
14
Ifosfamide
13
Cisplatin
13
Docetaxel
12
Specimen Handling
11
Etoposide
11
olaparib
9
Peripheral Blood Stem Cell Transplantation
9
Magnetic Resonance Spectroscopy
8
fludarabine
6
Temozolomide
6
Ipilimumab
6
Fluorouracil
6
Biopsy
6
Albumin-Bound Paclitaxel
6
rucaparib
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Thiotepa
5
Taxes
5
Standard of Care
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Blood Component Removal
×
Genitourinary
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled